Limited Competition for Continuation of the Integrated Islet Distribution Program (U24 Clinical Trial Not Allowed)

0
107

Funding Opportunity ID: 329170
Opportunity Number: RFA-DK-20-509
Opportunity Title: Limited Competition for Continuation of the Integrated Islet Distribution Program (U24 Clinical Trial Not Allowed)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Food and Nutrition
Health
Category Explanation:
CFDA Number(s): 93.847
Eligible Applicants: Others (see text field entitled “Additional Information on Eligibility” for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Eligible Agencies of the Federal Government; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Agency Code: HHS-NIH11
Agency Name: Department of Health and Human Services
National Institutes of Health
Posted Date: Sep 22, 2020
Close Date: Feb 09, 2021
Last Updated Date: Sep 22, 2020
Award Ceiling: $2,000,000
Award Floor: $0
Estimated Total Program Funding:
Expected Number of Awards:
Description: This Funding Opportunity Announcement (FOA) invites one application from the Program Director(s)/Principal Investigator(s) of the current Integrated Islet Distribution Program (IIDP) to renew the program andmaintain support for its continuing mission to provide the scientific community with important islet resources for diabetes research.The IIDP facilitates the distribution of human islets to biomedical researchers byestablishing partnerships with qualified islet isolation facilities to prepare and distribute human islets. The programmanages an application process to establish investigator eligibility to receive islet shipments, informs investigators of islet availability, manages a cost recovery system through fees collected from islet recipients, and oversees standardized phenotypic and genotypic analyses of islet preparations distributed throughout theIIDP network. Human islets remain an essential resource for diabetes research to advance our understanding of human islet cell biology, and to promote the development of new therapiesfor the prevention and treatment of diabetes.
Version: 1





Visit the Official Webpage For More Details on Limited Competition for Continuation of the Integrated Islet Distribution Program (U24 Clinical Trial Not Allowed)

LEAVE A REPLY

Please enter your comment!
Please enter your name here